Drug Profile


Alternative Names: UCB0942

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator UCB
  • Class Antiepileptic drugs; Imidazoles; Pyrrolidinones; Small molecules; Thiadiazoles
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Epilepsy

Most Recent Events

  • 14 Aug 2017 UCB Biopharma completes a phase I trial in Epilepsy (In volunteers) in United Kingdom (PO) (NCT03168984)
  • 01 Jul 2017 UCB completes a phase II trial in Epilepsy (Treatment-resistant) in Bulgaria, Belgium, Netherlands, Germany, Hungary and Spain (PO) (NCT02495844)
  • 09 Jun 2017 Chemical structure information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top